National Institute for Health and Care Excellence (NICE)

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell […]

The National Institute for Health and Care Excellence (NICE) has approved a combination of Imbruvica (ibrutinib) and venetoclax for all untreated chronic lymphocytic leukaemia (CLL) patients in England. The oral, fixed-duration combination treatment for adult CLL patients has been approved as first-line therapy and has been shown to be more effective than existing treatments. NICE’s […]

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab).  The drug is approved for use within NHS England and NHS Wales and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma who are inadequately controlled with high dose inhaled […]

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The recommendation will grant patients in […]

The National Institute for Health and Care Excellence (NICE) has published its Final Guidance recommending Translarna (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales.   Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged two years and older who can walk.  The final […]

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who […]

NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy.  Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat over 4,000 patients in England.    […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  Gene therapies have made the headlines over the last week, with treatments for rare AADC deficiency, lung cancer and haemophilia B given […]

News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer  Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first immunomodulatory treatment for type 1 diabetes approved in the […]

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.  The decision makes the relugolix combination therapy the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist […]